Innovation Pharmaceuticals Inc (IPIX)

[KMBJN]

Right, maybe if they give 600 mg, they will have 120% of the subjects respond! And even though prurisol is not an IL-20 inhibitor / antibody like other drugs, since IL-20 is reduced when treating psoriasis with prurisol, then every other disease in the world with increased IL-20 will be successfully treated by prurisol, despite not having any idea how prurisol works to reduce IL-20 in psoriasis, or having any supportive preclinical data in these other diseases or any mention of these other disease in the prusisol patent.

I hope that prurisol will work in moderate-to-severe psoriasis patients at higher doses (3 or 400 vs 200 mg in last trial). Right now the evidence is that at 200 mg, 7/20 (or 7/27 in intent-to-treat group) with mild-to-moderate disease responded to prurisol vs. only 3/18 to placebo. For those with moderate psoriasis, the percentage was higher, at 6/13 (haven't seen #s for placebo, assume something like 2/12 respond). It would be great if we can replicate that in a larger group of subjects / bigger trial, or even improve on that with higher doses, while keeping the AEs relatively rare and mild (increased LFT, headache, etc...).

I wonder what were the protocol deviations that caused them to get rid of 18 non-responders and 1 responder out of less than 60 subjects combined in the 200 mg and placebo arms.